Skip to main content
Clinical Trials/NCT04253509
NCT04253509
Completed
Not Applicable

Clinical Utility of Circulating Tumor DNA Methylation in the Diagnosis of Primary Lung Cancer

Samsung Medical Center1 site in 1 country280 target enrollmentFebruary 3, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer
Sponsor
Samsung Medical Center
Enrollment
280
Locations
1
Primary Endpoint
Diagnostic sensitivity of ctDNA methylation sequencing
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study aims to investigate the utility of circulating tumor DNA (ctDNA) methylation sequencing in the diagnosis of primary lung cancer.

Detailed Description

Plasma sample of patients with and without lung cancer will be collected and analyzed using methylation-sensitive enzyme sequencing method. Diagnostic performance of ctDNA methylation sequencing will be compared with that of tumor markers (CEA, Cyfra 21-1, and NSE) combined.

Registry
clinicaltrials.gov
Start Date
February 3, 2020
End Date
January 31, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sang-Won Um

Professor

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

  • Lung cancer group
  • Pathologically proven lung cancer
  • Clinically suspected lung cancer on chest CT scan
  • Benign pulmonary disease group
  • Chronic obstructive pulmonary disease, interstitial lung disease, pneumonia, bronchiectasis, non-tuberculous mycobacterial lung disease, pulmonary vascular disease

Exclusion Criteria

  • Patients with previous history of lung cancer
  • Patients who have been diagnosed with other malignancy within 5 years
  • Unstable vital status
  • Active pulmonary tuberculosis
  • Infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)

Outcomes

Primary Outcomes

Diagnostic sensitivity of ctDNA methylation sequencing

Time Frame: 2 year

Using pathologic diagnosis of lung cancer as gold standard, diagnostic sensitivity of ctDNA methylation will be compared with that of tumor markers.

Diagnostic specificity of ctDNA methylation sequencing

Time Frame: 2 year

Using pathologic diagnosis of lung cancer as gold standard, diagnostic specificity of ctDNA methylation will be compared with that of tumor markers.

Secondary Outcomes

  • Negative predictive value of ctDNA methylation sequencing(2 year)
  • Positive predictive value of ctDNA methylation sequencing(2 year)
  • Diagnostic accuracy of ctDNA methylation sequencing(2 year)

Study Sites (1)

Loading locations...

Similar Trials